Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Allogene
Biotech
Allogene lays off 28% of staff to save cash amid program delays
The off-the-shelf CAR-T cell therapy specialist disclosed the changes alongside delays to two CAR-T milestones.
Nick Paul Taylor
May 14, 2025 8:00am
Allogene’s lymphoma data show CAR-T could ‘leapfrog’ competition
Feb 14, 2025 10:35am
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Nov 14, 2024 5:59am
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Nov 8, 2024 4:47am
How to get cell therapies flying off-the-shelf
May 31, 2024 9:00am
Cell therapy reckoning: An unmet need remains in oncology
May 30, 2024 10:00am
